Treatment with a luteinising hormone-releasing hormone analogue (Buserelin) in danazol-resistant endometriosis patients

Franssen AM, Anton M.H.W. Franssen, A M Franssen, R. Rolland, Rolland R, Dev R. Chadha, Chadha DR, D R Chadha, W N Willemsen, Willemsen WN, Wim N.P. Willemsen, Vemer HM, H M Vemer
European journal of obstetrics, gynecology, and reproductive biology · 1986 · vol. 23(5-6) , pp. 379–386 · doi:10.1016/0028-2243(86)90173-5 · PMID:3100357 · W2040632335
Case report OA: closed CC0 ⤵ 3 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-07-03 ⓘ

Buserelin treatment was evaluated in patients with endometriosis who did not respond to danazol therapy.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Luteinising hormone-releasing hormone agonist (Buserelin) therapy administered for a period of 6 months in 4 patients with longstanding, severe, danazol-resistant endometriosis, was found to be effective in reducing all complaints related to endometriosis. From 2 weeks on, nearly half of the E2 determinations were below the sensitivity level of the assay, while the other values were predominantly in the range of the early follicular phase. Side effects associated with the induced hypoestrogenemia were mild and well tolerated. After six months of follow-up without treatment, one patient who desired pregnancy conceived shortly after cessation of therapy and one patient showed lasting amelioration of her complaints. The symptoms relapsed in the other two, possibly due to inadequate dose and/or duration of treatment.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Buserelin Danazol Endometriosis Pregnadienes Adult Adult Buserelin Buserelin Buserelin Danazol Danazol Drug Resistance Drug Resistance Endometriosis Endometriosis Endometriosis Estradiol Estradiol Estradiol Female

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (12)

Cited by (3)

Source provenance

europepmc
last seen: 2026-10-14T06:08:39.101224+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:24:24.182414+00:00
unpaywall
last seen: 2026-10-14T06:23:58.021457+00:00
License: CC0 · commercial use OK